[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cannabis-use\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cannabis-use":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,47,79,103,151,177,199,220,245,269,294,316,341,367,390,419,437,461,491,514,540,571,592,619,642],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100584583","study-of-an-oral-fluid-testing-approach-100584583",false,"NCT06891235","Study of an Oral Fluid Testing Approach","Oral Fluid Testing to Assess Cannabis Non-Use in Remote Clinical Trials","SOFTA","Inclusion Criteria:\n\n* Age 18 to 30 years\n* Cannabis use on \\>=1x\u002Fweek in the past 30 days\n* Ownership of a portable device that is capable of videoconference and videorecording (i.e., smartphone, tablet computer, or laptop computer)\n* Ability to read and speak English\n* Availability for duration of the study (3-4 weeks).\n* To proceed to oral fluid testing, positive result for urinary TCH-COOH\n\nExclusion Criteria:\n\n• Inability\u002Funwillingness to provide contact information","ALL","18 Years","30 Years",{"count":22,"type":23},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify and evaluate oral fluid testing as a biologic measure of cannabis use days that can be assessed remotely. The researchers will conduct this fully virtual study among a community sample of 200 individuals aged 18-30 years who have used cannabis at least 1 time per week on average in the past 30 days. Participants will complete oral fluid (saliva) tests, urine tests, and Timeline Follow-back interviews (self-report) that indicate their recent cannabis use (delta-9-THC). Participants will present for 3 virtual study visits across \\~3-4 weeks and be asked to complete activities in between: Study Visit 1 (Day 0; informed consent, baseline survey, TLFB interview), Study Visit 2 (\\~Day 7; TLFB interview, urine testing), 6 days of at-home videorecorded oral fluid testing, Study Visit 3 (\\~Day 21; TLFB interview, urine test, oral fluid test, survey, interview).",[27,28,29],"Cannabis Use","Cannabis Intoxication","Cannabis Use Disorder",[31,32,33],"cannabis use","young adult","oral fluid testing","RECRUITING","2026-06-27",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":40,"type":38},"2025-10-27",{"date":42,"type":23},"2027-05",{"name":44,"class":45},"Boston Children's Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100641909","phase-1-cannabis-and-opioid-use-disorder-study-2-100641909","NCT07661446","Cannabis and Opioid Use Disorder, Study 2","Inclusion Criteria:\n\n* Participants with moderate to severe opioid use disorder\n\nExclusion Criteria:\n\n* Individuals who do not use opioids or do not experience opioid withdrawal when they stop using opioids","55 Years",{"count":55,"type":23},100,"INTERVENTIONAL",[58],"PHASE1","This inpatient study enrolls healthy individuals who have opioid use disorder. Participants live at the University of Kentucky Hospital for approx. 6 weeks. During this time, we will examine how repeated doses of oral cannabis and acute doses of oral and inhaled cannabis 1) modify the intensity and time course of opioid withdrawal, 2) modify the effects of intranasal opioid administration and 3) impact the safety of opioid administration.",[61,27],"Opioid Use Disorders",[63,64,65,66,67,68],"Cannabis","marijuana","opioid","opioid use disorder","opioid withdrawal","opioid interaction","NOT_YET_RECRUITING","2026-06-22",{"date":72,"type":38},"2026-06-26",{"date":74,"type":23},"2026-07-30",{"date":76,"type":23},"2030-01-30",{"name":78,"class":45},"University of Kentucky",{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":53,"enrollmentInfo":86,"targetDuration":4,"studyType":56,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100643978","phase-1-cannabis-effects-on-opioid-self-administration-100643978","NCT07668635","Cannabis Effects on Opioid Self-Administration","Impact of Cannabis on Opioid Self-Administration","Inclusion Criteria:\n\n* Participants with moderate to severe opioid use disorder who experience opioid withdrawal\n* No allergies or adverse reactions to cannabis or opioids\n* Willing to stay inpatient at the UK Hospital research center for approx. 6 weeks\n\nExclusion Criteria:\n\n* Individuals seeking treatment for opioid use disorder",{"count":87,"type":23},30,[58],"The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive\u002Fdesire to take opioids.",[91,27],"Opioid Use Disorder",[93,94],"opioid use","cannabis","2026-06-19",{"date":97,"type":38},"2026-06-25",{"date":74,"type":23},{"date":100,"type":23},"2031-07-30",{"name":102,"class":45},"Shanna Babalonis, PhD",{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":18,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":56,"phases":115,"briefSummary":117,"conditions":118,"keywords":142,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":46},"100619125","neuroimaging-of-adolescent-cannabis-use-treatment-100619125","NCT07340554","Neuroimaging of Adolescent Cannabis Use Treatment","Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment","ACT","Inclusion Criteria:\n\n* 14-17 year old youth\n* Guardian 18 years or older\n* Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and\u002For hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant\n* Youth must endorse having used cannabis at least once per week over the past month OR youth must have been diagnosed with cannabis use disorder within the past three months\n\nExclusion Criteria:\n\n* Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent\u002Fguardian report\n* Youth or caretaker who is monolingual non-English speaker\n* Youth who is currently experiencing active psychosis symptoms or suicidal\u002Fhomicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality\u002Fhomicidality\n* Youth who is currently undergoing contingency management treatment for cannabis use disorder","14 Years","17 Years",{"count":114,"type":23},80,[116],"NA","This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.",[27,119,29,120,28,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141],"Cannabis Dependence","Cannabis Abuse","Cannabis Smoking","Cannabis Withdrawal","Cannabis-Related Disorder","Cannabis Abuse, in Remission","Cannabis Abuse, Episodic Use","Marijuana","Marijuana Abuse","Marijuana Use","Marijuana Smoking","Marijuana Dependence","Marijuana User","Marijuana-Related Disorder","Marijuana Use Disorder","Addiction","Addiction, Substance","Substance Use","Substance Use Disorders","Substance Dependence","Substance Abuse","Substance Related Problem","Substance Abuse Drug Chronic",[63,126,134],"2026-06-18",{"date":70,"type":38},{"date":146,"type":38},"2026-06-15",{"date":148,"type":23},"2030-05-01",{"name":150,"class":45},"Indiana University",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":18,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":56,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":46},"100620425","smart-talk-cannabis-awareness-and-prevention-curriculum-evaluation-100620425","NCT07357454","Smart Talk: Cannabis Awareness and Prevention Curriculum Evaluation","Evaluation of the Smart Talk: Cannabis Awareness and Prevention Curriculum","Inclusion Criteria:\n\n* Middle school and high school students receiving health education at schools participating in the study\n\nExclusion Criteria:\n\n\\-",true,"10 Years","20 Years",{"count":162,"type":23},10800,[116],"The Stanford REACH Lab's SMART TALK: Cannabis Awareness and Prevention Toolkit is a free, online educational resource to be used by educators to increase knowledge and awareness of cannabis and reduce use among youth. The aim of this study is to investigate the extent to which the curriculum changes middle and high school students' intentions to use and actual use of cannabis.",[27],[167],"youth cannabis education health prevention","2026-06-05",{"date":170,"type":38},"2026-06-08",{"date":172,"type":23},"2026-09",{"date":174,"type":23},"2030-02",{"name":176,"class":45},"Stanford University",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":18,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":56,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":46},"100643636","transcranial-magnetic-stimulation-for-adolescents-and-young-adults-with-cannabis-use-disorder-100643636","NCT07634835","Transcranial Magnetic Stimulation for Adolescents and Young Adults With Cannabis Use Disorder","Inclusion Criteria:\n\n* 15-21 years old\n* For minors, parent\u002Flegal guardian able to provide consent and child able to provide assent; for adults, ability to self-consent per MacArthur Competence Assessment Tool for Clinical Research\n* Ability to comply with study procedures\n* Treatment-seeking youth diagnosed with CUD as per the Mini-International Neuropsychiatric Interview (MINI-KID (Sheehan et al., 2010) for 15-17 years old and MINI (Sheehan et al., 1998) for 18-21 years old)\n* Cannabis use 3+ days per week (or 12+ days in the past month) as verified by Timeline Followback (TLFB) (Sobell \\& Sobell, 1996)\n* Fluent in spoken English\n\nExclusion Criteria:\n\n* Medical conditions contraindicated or associated with altered TMS risk profile, including history of intracranial pathology, intracranial lesions, epilepsy or seizure disorders, or individuals with a family history of epilepsy or seizure in a first degree relative, traumatic brain injury, brain tumor, stroke, neurocardiogenic syncope, mania\u002Fbipolar disorder, implanted medical devices or metallic objects in the head, current pregnancy or not using effective contraception if capable of becoming pregnant, or any other serious medical condition or contraindication as judged by the study physician; moderate to severe heart disease, pediatric populations with risk factors for neurocardiogenic syncope (history of syncope\u002Fpresyncope related to noxious stimuli, anxiety, micturation, or posture)\n* Inability to undergo MRI.\n* Diagnosis of psychosis, cognitive disability or active suicidality. The MINI (Sheehan et al., 1998, 2010) will be used to assess current psychiatric comorbidities and the Ask Suicide-Screening Questions (ASQ) will be used to assess suicidality (Horowitz et al., 2012).\n* Primary current alcohol or substance use disorder, except for caffeine or nicotine.\n* Taking a medication with high seizurogenic potential (e.g., clomipramine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, anti-psychotics, lithium, bupropion -e.g. Wellbutrin). Participants taking psychotropic medications will be included if dose is stable for ≥4 weeks with no anticipated changes during the study period. All concurrent treatments will be monitored during the study period.\n\n  * If an individual is currently taking antibiotics that affect the central nervous system such as Fluoroquinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin) or Imipenem, medications that have the potential of lowering seizure threshold, participation in the study will be delayed until 5 days after the last antibiotic dose.\n  * If an individual is taking antihistamines (i.e. Benadryl\u002Fdiphenhydramine), they will be asked to refrain from using the antihistamine for at least 24 hours before the TMS session. If the participant is not able to do so, they will be excluded from the study.","15 Years","21 Years",{"count":186,"type":23},50,[116],"This pilot study will investigate the potential of repetitive transcranial magnetic stimulation (rTMS) to strengthen a neural circuit critical for maintaining abstinence in adolescents and youth with cannabis use disorder (CUD).",[27,29],"2026-06-02",{"date":192,"type":38},"2026-06-09",{"date":194,"type":23},"2027-03-01",{"date":196,"type":23},"2029-03-31",{"name":198,"class":45},"University of Minnesota",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":158,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":56,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":46},"100633307","joint-effort-20--evaluation-among-general-population-100633307","NCT07524985","Joint Effort 2.0 : Evaluation Among General Population","\" Joint Effort 2.0 \" Une Application Mobile de prévention et de réduction Des méfaits: évaluation auprès de Consommateurs de Cannabis","Inclusion Criteria:\n\n* Aged 18 years old or older\n* Be an active non-medical cannabis user (ie. self reported past month usage)\n* Understand, read and write French\n* Own a smartphone (iPhone)\n\nExclusion Criteria:\n\n* None",{"count":207,"type":23},110,[116],"This study aims to evaluate a mobile app designed to promote the safe use of cannabis among adult users in Quebec.",[27],"2026-06-01",{"date":213,"type":38},"2026-06-03",{"date":215,"type":38},"2026-04-30",{"date":217,"type":23},"2027-04",{"name":219,"class":45},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":158,"sex":18,"minAge":184,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":56,"phases":228,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":46},"100615766","phase-2-acute-effects-of-cannabis-on-cognition-and-affect-100615766","NCT07296874","Acute Effects of Cannabis on Cognition and Affect","Inclusion Criteria:\n\n* be 21 years of age or older\n* be fluent in English\n* use of cannabis at least once a week for at least one year\n* inhalation as their typical method of administration\n* be willing to abstain from cannabis on the day of their scheduled testing session\n\nExclusion Criteria:\n\n* neurological conditions (e.g., neurodegenerative disorders, severe head injury, multiple concussions)\n* serious psychiatric conditions (e.g., psychosis, bipolar disorder)\n* family history of psychosis\n* intellectual disabilities or learning disorders (e.g., dyslexia)\n* chronic medical conditions that affect cognition or increase risk of cannabis use or exposure to cold water (e.g., heart disease, diabetes, Reynaud's disease, history of frostbite, peripheral neuropathy, history of fainting or seizures, fractures or wounds on both hands or wrists),\n* heart disease\n* BMI \\> 34\n* pregnant or lactating\n* use of illicit drugs in past 6 months\n* heavy use of alcohol (drinking \\>4 drinks \\>4 times per week)\n* nicotine\u002Ftobacco use\n* have experienced a severe adverse reaction to cannabis (e.g., panic attack, psychosis)",{"count":227,"type":23},90,[229],"PHASE2","This study will examine how a moderate dose of THC affects mood, stress responses, and cognitive functioning in regular cannabis users. The study uses a double-blind, placebo-controlled, crossover design, meaning each participant will complete two sessions. Specifically, each participant will be given active cannabis (20 mg THC) in one session, and placebo in the other session. The order will be randomized across participants, so half will receive cannabis first, and the other half will receive placebo first.\n\nNinety adults who use cannabis at least weekly will be recruited from the local community. After an online screening survey, eligible participants will attend a laboratory visit where the participants will provide informed consent and complete saliva and urine drug tests to confirm recent abstinence from cannabis and absence of other drugs. Participants who pass screening will complete baseline questionnaires of cannabis use patterns, depression, anxiety, ADHD symptoms, emotion regulation, affect, and demographic information.\n\nCannabis and placebo materials (obtained from NIDA) will be vaporized using a Volcano vaporizer device. Participants will inhale the vapor under supervision, and neither the participant nor the researcher assessing outcomes will know which product is administered. After vaping, participants will complete repeated mood ratings, saliva samples, and a battery of cognitive tests assessing executive functions like planning, inhibition, working memory, and cognitive flexibility.\n\nParticipants will also complete a standardized stress challenge (the Maastricht Acute Stress Test), which involves repeated trials of placing their hand in cold water and doing challenging mental math, followed by additional mood ratings and saliva samples. The participants will then watch a nature video and report their feelings of awe and affect.\n\nAt the end of each session, participants will remain in a supervised room with entertainment and snacks until at least four hours have passed since vaping and the participants report feeling sober. The participants will then return for a second session with the opposite study condition (THC or placebo) one week later. Both sessions follow the same procedures. Participants are fully debriefed after completing the study.",[27],[63,233,234,235,236],"THC","Executive functioning","Stress reactivity","Affect","2026-05-28",{"date":211,"type":38},{"date":240,"type":23},"2026-07",{"date":242,"type":23},"2028-05",{"name":244,"class":45},"Washington State University",{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":158,"sex":18,"minAge":19,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":56,"phases":253,"briefSummary":254,"conditions":255,"keywords":259,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":46},"100608046","precision-brain-stimulation-to-reduce-cannabis-craving-in-schizophrenia-100608046","NCT07196462","Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia","Inclusion Criteria for Psychosis Participants:\n\n* Age between 18-65 years\n* Diagnosis of a psychotic disorder according to DSM-5 criteria and confirmed by SCID\n* Current cannabis use of at least 2\u002F10 on a Visual Analog Scale\n* Current cannabis use (confirmed by urine cannabis testing)\n* Must be able to read, speak and understand English\n* Must be judged by study staff to be capable of completing the study procedures\n* Participants will be in stable outpatient psychiatric treatment and psychiatrically stable with no recent (within the past 30 days) psychiatric hospitalizations or changes in their psychiatric medication regimens.\n\nInclusion Criteria for Healthy Controls:\n\n\\- All of the above except for participants will not have a diagnosis of a psychotic disorder nor a first-degree relative with a psychotic disorder.\n\nExclusion Criteria for ALL participants:\n\n* DSM-5 intellectual disability\n* Substance use disorder (other than cannabis or nicotine) within the past three months\n* Positive urine drug screen for illicit substance use that can increase seizure risk (cocaine, benzodiazepines, amphetamine, methamphetamine)\n* Any history of a progressive or genetic neurologic disorder (e.g. Parkinson's disease, multiple sclerosis, tuberous sclerosis, Alzheimer's Disease) or acquired neurological disease (e.g. stroke, traumatic brain injury, tumor), including intracranial lesions\n* History of head trauma resulting in any loss of consciousness (\\>15 minutes) or neurological sequelae\n* Current history of poorly controlled headaches including chronic medication for migraine prevention\n* History of fainting spells of unknown or undetermined etiology that might constitute seizures\n* History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family history epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement)\n* Any devices such as pacemaker, medication pump, nerve stimulator, TENS unit, ventriculo-peritoneal shunt unless cleared by the responsible covering MD\n* All female participants of child-bearing age will be required to have a pregnancy test; any participant who is pregnant or planning to become pregnant will not be enrolled in the study\n* Medications will be reviewed by the responsible covering physician and a decision about inclusion will be made based on the participant's past medical history, drug dose, history of recent medication changes or duration of treatment, and use of CNS active drugs. The published TMS guidelines review of medications to be considered with rTMS will be taken into consideration given their described effects on cortical excitability measures.\n* Any changes in medications or hospitalizations within the past 30 days.\n* Participants who, in the investigator's opinion, might not be suitable for the study or would be unable to tolerate the study visit\n\nThese exclusion criteria strictly follow all recommended guidelines as endorsed by the International Federation of Clinical Neurophysiology and the International Society for Transcranial Stimulation.","65 Years",{"count":55,"type":23},[116],"The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cue-induced craving and cognitive performance in individuals with schizophrenia and schizoaffective disorder, while targeted stimulation of the L DLPFC leads to these changes in healthy controls who use cannabis. This study will test a model that integrates brain network pathophysiology and cognition to 1) explain the prevalence of cannabis use in schizophrenia and 2) identify a target for engagement in schizophrenia. This study seeks to establish a neuroscientific framework to guide future treatment-oriented studies aimed at reducing craving and improving cognitive performance in individuals with schizophrenia and schizoaffective disorder.\n\nThis is a study of the effect of 2 rTMS interventions on functional connectivity and craving in individuals with schizophrenia or schizoaffective disorder and healthy controls who use cannabis.\n\nAim 1: Target Engagement: Determine if rTMS manipulates functional connectivity of each target (DMN, L DLPFC) (n=100).\n\nAim 2: Clinical Efficacy: Determine if rTMS affects cue-induced craving and if craving change correlates with change in functional connectivity (n=100).\n\nAs an exploratory analysis, the factors that explain individual variance in rTMS-induced connectivity change will also be explored.",[27,256,257,258],"SCHIZOPHRENIA","Psychosis","rTMS",[31,260,258,261],"schizophrenia","brain stimulation",{"date":190,"type":38},{"date":264,"type":38},"2026-01-15",{"date":266,"type":23},"2027-12-31",{"name":268,"class":45},"Vanderbilt University Medical Center",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":158,"sex":18,"minAge":19,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":56,"phases":278,"briefSummary":279,"conditions":280,"keywords":283,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":46},"100543105","phase-1-examining-the-role-of-tolerance-on-dose-dependent-effects-of-acute-thc-on-oculomotor-and-cognitive-performance-100543105","NCT06351540","Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance","Inclusion Criteria:\n\n* Inclusion criteria: Healthy non-treatment seeking adults (age 18 to 60, N = 40) who report\n* (a) infrequent cannabis use defined as at least one reported use in the past year with a negative THC urine toxicology at baseline, or\n* (b) report frequent cannabis use defined as \\> 5 days per week for \\> 1 year with a positive THC urine toxicology at baseline.\n\nThese criteria were selected to target individuals with low and high-frequency cannabis use in order to examine the direct effect of tolerance on study outcome measures.\n\nExclusion Criteria:\n\n* (1) meet DSM-V criteria for substance use disorders other than tobacco, cannabis, or caffeine,\n* (2) are currently receiving or interested in immediately receiving behavioral treatment or medication for cannabis cessation,\n* (3) current use of any medications that could affect study outcomes,\n* (4) test positive for drugs of abuse (other than cannabis) and\u002For breath alcohol test at study admission,\n* (5) have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity,\n* (6) are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding,\n* (7) have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g. Prinzmetal's angina), or (8) are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.","60 Years",{"count":277,"type":23},40,[58],"The purpose of this research is to determine the extent to which oculomotor function accurately detects THC-impairment, if cannabis use experience impacts this detection threshold, and to examine how the oculomotor index corresponds to a measure of sustained attention. A double-blind, placebo-controlled, within-subjects crossover design will be used to examine the dose-effects of THC (0, 5mg, 30mg) on oculomotor performance tasks and a sustained attention task in frequent and infrequent cannabis users. Results from the study will advance the investigators' understanding of the effect of THC and cannabis use frequency on oculomotor function and sustained attention, and will directly inform the validity of the investigators' oculomotor platform for identifying acute THC- induced impairment in frequent and infrequent users.",[27,281,282],"Impaired Driving","Cognitive Impairment",[94,233,284],"impairment","2026-05-26",{"date":287,"type":38},"2026-05-27",{"date":289,"type":23},"2026-08-01",{"date":291,"type":23},"2027-07-01",{"name":293,"class":45},"Johns Hopkins University",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":158,"sex":18,"minAge":184,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":56,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":46},"100609617","evaluating-the-impact-of-psychotherapeutic-advertising-claims-on-cannabis-purchasing-100609617","NCT07216911","Evaluating the Impact of Psychotherapeutic Advertising Claims on Cannabis Purchasing","Inclusion Criteria:\n\n* Age 21 years or older\n* Current residence in the United States\n* Cannabis use on 1-100 days in the past year\n* Current symptoms of mild to severe depression and\u002For generalized anxiety disorder, assessed by PHQ-8 (score ≥ 5) and GAD-7 (score ≥ 5)\n\nExclusion Criteria:\n\n* Under 21 years of age\n* Not currently residing in the United States",{"count":301,"type":23},2000,[116],"In the U.S., legal cannabis is frequently advertised as an effective treatment for mental health problems such as anxiety and depression-particularly online. States that have legalized cannabis have not implemented regulations to address this type of advertising. This project aims to investigate the influence of psychotherapeutic advertising claims (PAC) and mental health warning labels (WL) on online cannabis purchasing behaviors among light-to-moderate cannabis users with symptoms of depression and\u002For anxiety.\n\nThe specific aims are to determine whether PAC increases cannabis purchasing intentions and whether a mental health WL can mitigate this effect. A realistic online cannabis shopping experience will be simulated using the digital Platform for Online Evaluation of Marijuana Marketing and Sales (POEMMS). The study will employ a between-subjects experimental design by randomizing 2,000 participants to one of four online stores that vary in PAC and WL content: (1) a control claims (CC)-only store, (2) a PAC store, (3) a WL store, and (4) a PAC + WL store. Participants will browse and select items as if making real purchases.\n\nAnalyses will examine three primary outcomes to determine the influence of PAC and WL on purchasing behaviors: (1) total milligrams of THC purchased, (2) average potency (%THC) of products, and (3) overall number of products purchased. The long-term objective is to inform evidence-based cannabis policy and regulatory strategies by understanding the impact of cannabis marketing on vulnerable populations.\n\nThis research is relevant to public health by addressing the potential risks associated with misleading cannabis marketing, which may lead to increased use and exacerbation of mental health symptoms among individuals with depression and anxiety. The project leverages a multidisciplinary team with expertise in addiction, mental health, epidemiology, and digital health technology. The findings have the potential to inform the development of targeted interventions and policies to reduce harms associated with cannabis advertising-ultimately contributing to better health outcomes and more effective regulation.",[305,306,27],"Anxiety","Depression","2026-05-19",{"date":309,"type":38},"2026-05-22",{"date":311,"type":38},"2026-04-15",{"date":313,"type":23},"2027-06-30",{"name":315,"class":45},"Trustees of Dartmouth College",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":158,"sex":18,"minAge":323,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":56,"phases":327,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":339,"locationsCount":46},"100473460","investigating-the-neural-correlates-of-cognitive-function-in-psychosis-patients-and-non-psychiatric-controls-with-cannabis-use-100473460","NCT05445180","Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Investigating the Neural Correlates of Cognitive Function Associated With Cannabis Abstinence in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Inclusion Criteria:\n\n* Able to provide informed consent in English or French\n* Heavy cannabis use (defined as weekly cannabis use for at six months) and\u002For DSM-5 diagnosis of CUD\n* Have a Full-Scale IQ ≥ 75\n* Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)\n* Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)\n* Clinically stable (as measured by the PANSS-6, total score \\\u003C30) (psychosis patient arm only)\n\nExclusion Criteria:\n\n* current SUD (other than CUD)\n* MRI contraindications\n* Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine\n* Current suicidal or homicidal ideation\n* Head injury requiring hospitalization or loss of consciousness \\> 5 minutes\n* Current medical diseases that requires hospitalization or regular monitoring\n* Being pregnant\n* DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only)\n* Taking psychotropic medication","16 Years","80 Years",{"count":326,"type":23},134,[116],"Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.",[330,29,119,27,331,332,333,334],"Psychotic Disorders","Schizophrenia; Psychosis","Cognitive Dysfunction","Memory Impairment","Neuroimaging",{"date":309,"type":38},{"date":337,"type":38},"2022-04-21",{"date":42,"type":23},{"name":340,"class":45},"Douglas Mental Health University Institute",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":158,"sex":18,"minAge":19,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":56,"phases":351,"briefSummary":352,"conditions":353,"keywords":356,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":4},"100548538","developing-and-testing-an-online-intervention-for-alcohol-and-cannabis-misuse-and-healthy-relationship-skills-among-young-adult-couples-100548538","NCT06422299","Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Young Adult Couples","Developing and Testing an Online Intervention for Decreasing Alcohol and Cannabis Misuse and Increasing Healthy Relationship Skills Among Young Adult Couples: A Comprehensive Mixed-methods Approach","Inclusion Criteria:\n\n* Both partners in the couple are 18-29 years old\n* In a committed romantic relationship (e.g., dating seriously, cohabiting, married) with each other for at least 3 months\n* Face-to-face contact their partner at least 5 days per week\n* Live in Washington State\n* Have a valid email address and access to a cell phone\n* Report alcohol and cannabis co-use at least three times in the past month\n* Willingness to: complete online surveys during the allotted time frames, receive text messages and emails from the project, complete a baseline session, and participate during the same time period as their partner\n\nExclusion Criteria:\n\n* Couples who endorse any perpetration or receipt of severe interpersonal aggression during screening will be excluded and provided with resources","29 Years",{"count":350,"type":23},60,[116],"The goal of this clinical trial is to develop and test a brief online intervention to reduce alcohol and cannabis misuse and improve healthy relationship skills among young adult couples. The main questions it aims to answer are:\n\n* Will the intervention be feasible and acceptable to young adult couples?\n* Will the intervention demonstrate initial efficacy in reducing risky substance use and increasing relationship functioning?\n\nEligible couples will complete a virtual baseline session and be randomized to intervention condition (online intervention with 3-5 weeks of self-paced modules) or control condition (no intervention). Couples will complete two follow-up surveys (post-assessment - approximately 5 weeks after baseline, 3-month). Couples in the control condition will be offered the intervention after 3-month follow-up.\n\nResearchers will compare intervention and control groups to see if there there is a difference between the groups on substance misuse and relationship functioning at post-assessment and 3-month follow-up.",[354,27,355],"Alcohol Drinking","Couples",[357],"alcohol use, cannabis use, couples, healthy relationships, young adults","2026-05-04",{"date":360,"type":38},"2026-05-06",{"date":362,"type":23},"2026-09-15",{"date":364,"type":23},"2027-08-01",{"name":366,"class":45},"University of Washington",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":56,"phases":377,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":389},"100448422","environment-and-lung-cancer-100448422","NCT05119244","Environment and Lung Cancer","ECP","Inclusion Criteria:\n\n* Any patient from 18 y.o to 59 y.o treated in one of the three above-mentioned hospitals for primary lung cancer, whatever its stage, and agreeing to participate in this research.\n\nExclusion Criteria:\n\n* Patient denied participation.","59 Years",{"count":376,"type":23},150,[116],"Cannabis is the most consumed drug in the world and the French are the main consumers in Europe. The most recognized effects of cannabis on human health are of a neuro-psychic nature. The medical literature on the effects of cannabis on the lung in general, and on lung carcinogenesis in particular, is most often reassuring (Tashkin, Chest 2018; Zhang, Int J Cancer 2015; Ghasemiesfe JAMA Netw. Open. 2019), despite the fact that the concentration of carcinogens in cannabis smoke is higher than that contained in tobacco smoke (Moir, Chem. Res. Toxicol. 2008), and that cannabis smoking has been implicated in the occurrence of ENT cancers. Rather, research focuses on the therapeutic effects of cannabis, especially analgesics, and even on its possible anti-tumor virtues (Abrams, Jama Oncol. 2020). These reassuring data should, however, be viewed with a great deal of caution. On the one hand, the illegal nature of cannabis in most countries and its frequent association with tobacco consumption make studies on the subject difficult and often biased. On the other hand, the daily practice of oncologists, who observe numerous cases of advanced and rapidly progressive lung cancer occurring in young patients who are heavy users of cannabis, raises suspicion of an unrecognized role of cannabis in lung carcinogenesis.\n\nIn a preliminary multicenter study on French patients under 50 years of age operated for primary lung cancer (Betser, ERJ 2021), we demonstrated that cannabis consumption was extremely frequent, concerning 43% of patients, but mentioned in patients' medical records only in 4 out of 10 cases, while the smoking status was always noted.\n\nIn addition, by comparing people who smoke cannabis (always here associated with tobacco) to patients who only smoke tobacco or to non-smokers, we identified a different profile of lung cancers, with more poorly differentiated tumors, presenting at a more advanced stage (more T3-T4 versus T1-T2) requiring more complex surgery, and mostly located in the upper lobes of the lung.\n\nSimilar research work is currently underway at Gustave Roussy (Dr Pradere-Dr Planchard, Villejuif, France) on patients with metastatic lung cancer, with a focus on overall survival and molecular profile.",[27],[381],"Cannabis, Lung Cancer",{"date":360,"type":38},{"date":384,"type":38},"2021-10-01",{"date":386,"type":23},"2027-02-01",{"name":388,"class":45},"Centre Chirurgical Marie Lannelongue",3,{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":158,"sex":18,"minAge":111,"maxAge":160,"enrollmentInfo":397,"targetDuration":4,"studyType":56,"phases":399,"briefSummary":400,"conditions":401,"keywords":402,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":418},"100588430","neural-and-psychiatric-consequences-of-cannabis-use-in-adolescents-100588430","NCT06941298","Neural and Psychiatric Consequences of Cannabis Use in Adolescents","Cann-Teen","Inclusion criteria at baseline.\n\n* Cannabis users: To capture a wide range of cannabis use frequency, meeting DSM-5 criteria for cannabis use disorder will not be required. However, in order to ensure sufficient exposure, we will require majority of adolescents with cannabis use to have a significant cannabis use (self-reported use on more or equal to 10 of the prior 30 days and positive THC urine toxicology).\n* Depression: Similarly, to capture a wide range of depression illness severity, we will allow participants with subthreshold depression, defined as a raw severity score of \\>=30 on the Children's Depression Rating Scale-Revised (CDRS-R, for ages 14-17) and as a raw severity score of \\>=12 on the Montgomery Asberg Depression Rating Scale (MADRS, for ages 18-20). However, we plan for at least 50% of participants with depressive symptoms to have a raw severity score of \\>=40 on the CDRS-R and of \\>=20 MADRS, which are considered reliable for depression. Additionally, we will allow participants with a research diagnosis of Major Depressive Disorder as defined by the MINI, even with a CDRS-R score below 30 or a MADRS score below 12. Moreover, because there could be individuals without MDD who have current depressive symptoms, individuals who lack a diagnosis of a depressive disorder but have a CDRS-R score of 30 (or higher) or a MADRS score of 12 (or higher) will be allowed. Through careful recruitment, we will ensure distributions of depression severity. Based on our prior studies employing similar criteria, we anticipate that anhedonia, anxiety and depression severity scores will be normally distributed in our samples.\n\nExclusion criteria.\n\nAll participants:\n\n* Psychotropic medication free for more than 1 month (or more than three months for medications with a long half-life such as fluoxetine) prior to study enrollment. We have successfully enrolled hundreds of psychotropic medication-free depressed adolescents and young adults to date. Psychotherapy will be allowed.\n* MRI contraindications such as claustrophobia, metallic ink tattoos, orthodontic braces, or pacemakers\n* Positive pregnancy tests\n* Neurological illnesses and medical conditions such as unique pain syndromes (e.g. multiple sclerosis, rheumatoid arthritis)\n* Estimated full-scale IQ \\\u003C=80 to ensure that participants have the ability to understand the study\n* Current SUD other than cannabis or nicotine. Excluding nicotine use will limit generalization of our findings and impact feasibility. Similarly, alcohol use will be allowed as long as it is not hazardous and does not meet criteria of a DSM-5 disorder (AUDIT-C \\>5). Therefore, nicotine and alcohol use will be allowed and controlled for. Alcohol and cannabis use (assessed based on breathalyzer from alcohol and self-report for cannabis\u002FTHC) on the day of the scan will result in rescheduling the scan as it can affect MRI data.\n* Certified for or self-reported medical cannabis use, or intent to become certified, current stimulant use (methamphetamine or cocaine) by self-report or urine toxicology. Adderall and Vyvanse for ADHD will be allowed as long as use is temporarily paused medication usage at least 3 days before neuroimaging visit. If medication is not discontinued on scan day, scanning at that time will be up to PI discretion.\n* Oral contraceptives will be allowed and controlled for in order to maximize recruitment of older adolescents.\n\nDepressed THC non-users:\n\n* DSM-5 diagnoses of bipolar disorder, psychotic disorders, autism spectrum disorders, and all non-cannabis substance-related disorders will be exclusionary. However, anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD) are not uncommon among depressed individuals and will be allowed as long as depressive symptoms are primary. Our focus on behavioral constructs aims to address comorbidity and mechanistic overlap among psychiatric disorders. Were these diagnoses exclusionary, the sample would be highly atypical of depression.\n* Self-injurious acts (e.g. cutting) and suicidal ideations (SI) without a specific plan (defined as passive SI) are common in adolescent depression and will be allowed. However, if SI constitutes an imminent risk to self or others (defined as active SI), the adolescent will be withdrawn from the study and emergency procedures will be initiated immediately, including ER admission (see Protection of Human Subjects).\n\nHealthy controls will have no lifetime history of any major psychiatric diagnoses and no use of any THC.",{"count":398,"type":23},280,[116],"The goal of this study is to investigate the effects of cannabis on brain function among adolescents with depression.",[27,306],[403,334,404,405,406,407,408],"Adolescents","Functional Magnetic Resonance Imaging (fMRI)","Reward","Reward Flanker Task","Reward Predication Error Task","Pain","2026-04-20",{"date":411,"type":38},"2026-04-22",{"date":413,"type":38},"2025-03-04",{"date":415,"type":23},"2029-06-01",{"name":417,"class":45},"University of Miami",2,{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":158,"sex":18,"minAge":184,"maxAge":53,"enrollmentInfo":425,"targetDuration":4,"studyType":56,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":46},"100485559","phase-1-the-impact-of-product-formulation-on-the-pharmacokinetics-and-pharmacodynamics-of-cannabis-edibles-100485559","NCT05602649","The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Cannabis Edibles","Inclusion Criteria\n\n* Have provided written informed consent.\n* Be between the ages of 21 and 55.\n* Be in good general health based on screening procedures (e.g., physical exam, medical history interview, vital signs, routine blood tests).\n* Test negative for illicit drugs (including cannabis) and test negative for alcohol (0% BAC) at screening and before any study sessions.\n* Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at admission for each session.\n* Have prior experience using THC-dominant cannabis.\n* Have a body mass index (BMI) in the range of 16 to 38 kg\u002Fm2.\n* Have not donated blood in the past 30 days.\n\nExclusion Criteria\n\n* Self-reported use of illicit drugs (e.g., amphetamine, cannabis, cocaine, methamphetamine, MDMA, LSD, ketamine, heroin, psilocybin, prescription medications not prescribed to the person) in the past 30 days.\n* History of significant allergic reaction or significant hypersensitivity to cannabis or to any of the other ingredients in the study products.\n* Current concomitant medication use that may interact with the study drug including inhibitors and inducers of CYP2CP and CYP3A4 as well as highly-protein bound drugs and drugs with a narrow therapeutic index such as warfarin, cyclosporine, and amphotericin B.\n* History of or current evidence of a significant medical condition that, in the opinion of the investigator or medical staff, will impact the participant's safety or interfere with study outcomes.\n* Evidence of current psychiatric condition (based on MINI for DSM-5).\n* Been in treatment previously for cannabis use disorder.\n* Receiving of any drug as part of a research study within the past 30 days.\n* History of epilepsy or other serious medical condition.",{"count":114,"type":23},[58],"This study will examine the pharmacokinetics and pharmacodynamics of delta-9-tetrahydrocannabinol (THC)-infused chocolates, gummies, and drinks. Healthy adults (N=40) will complete 9 drug administration sessions, including an overnight stay prior to each session. Participants will consume THC containing products in a fasted state; following drug administration, the participants will complete cognitive and psychomotor tasks, subjective assessments, have blood collected, and vital signs monitored.",[27],"2026-04-09",{"date":431,"type":38},"2026-04-13",{"date":433,"type":38},"2024-07-10",{"date":435,"type":23},"2027-01",{"name":293,"class":45},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":158,"sex":18,"minAge":184,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":56,"phases":445,"briefSummary":446,"conditions":447,"keywords":450,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":46},"100562895","phase-1-effect-of-cannabis-on-e-cigarette-use-behavior-100562895","NCT06609109","Effect of Cannabis on E-Cigarette Use Behavior","Effect of Cannabinoids on Tobacco Product Demand and Pharmacodynamics: Electronic Cigarette Use","Inclusion criteria:\n\n1. Healthy non-treatment seeking adults aged 21 or older\n2. Report daily use of e-cigarettes\n3. Biological confirmation of e-cigarette use: have a positive urine cotinine test at screening\n4. Report current use of cannabis (at least 1 occasion per week)\n5. Have experience with the inhalation route of administration for cannabis\n6. Biological confirmation of cannabis use: have a positive urinary THC drug test at screening.\n7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study.\n\nExclusion criteria:\n\n1. Report current intention to reduce or quit cannabis or tobacco use within the next 30 days\n2. Meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine\n3. Test positive for illicit drugs other than cannabis and tobacco\n4. Positive breath alcohol test at study admission\n5. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity\n6. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n7. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding\n8. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina)\n9. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.",{"count":55,"type":23},[58],"The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of electronic cigarettes. The study's goals are to test demand for e-cigarettes, tobacco craving, affect, heart rate, blood pressure, expired breath carbon monoxide, and cognitive performance. Researchers will compare multiple doses of THC and a placebo in participants who smoke e-cigarettes and either smoke or vape THC in the laboratory.",[27,448,449],"Tobacco Use","Electronic Cigarette Use",[94,451,452,64,233,453],"e-cigarette","electronic cigarette","Tobacco","2026-04-08",{"date":429,"type":38},{"date":457,"type":38},"2025-03-19",{"date":459,"type":23},"2029-10-01",{"name":293,"class":45},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":158,"sex":18,"minAge":19,"maxAge":469,"enrollmentInfo":470,"targetDuration":4,"studyType":56,"phases":472,"briefSummary":473,"conditions":474,"keywords":477,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":46},"100573214","cannabis-effects-on-sleep-circadian-rhythms-and-light-sensitivity-in-young-adults-100573214","NCT06743373","Cannabis Effects on Sleep, Circadian Rhythms, and Light Sensitivity in Young Adults","Cannabis Effects on Sleep, Circadian Rhythms, and Light Sensitivity in Young Adults (CASCILS)","CASCILS","List the inclusion criteria:\n\n* Age 18-25 years\n* Physically and psychiatrically healthy, as determined by instruments described below\n* Cannabis-Using group only: Regular cannabis use, defined as \"frequent\" (6-29 days\u002Fmonth) or \"daily\" (daily) use over the past 3 months\n* Cannabis-Using group only: Willingness to discontinue cannabis for 4 weeks.\n* Control group only: No cannabis use in the past 3 months. Deny engaging in daily or near-daily cannabis use during the past year. No history of alcohol and\u002For substance use disorders. No current sleep disorders (including insomnia and delayed sleep phase disorder).\n* Provision of written informed consent\n\nList the exclusion criteria:\n\n* Significant or unstable acute or chronic medical conditions. Examples of such conditions include, but are not limited to, central nervous system disorders (e.g., head injury, seizure disorder, multiple sclerosis, tumor), cardiovascular or hemodynamically significant cardiac disease, liver disease (e.g., acute or chronic hepatitis, hepatic insufficiency), migraine or chronic headaches, active peptic ulcer disease, inflammatory bowel disease, renal failure, arthritis, and diabetes and other endocrine disorders. Seizure disorder in particular will be exclusionary due to the increased risk it confers for cannabis withdrawal symptoms. Eye\u002Fretinal conditions such as diabetic retinopathy or glaucoma will be exclusionary, although should be very rare in this population. Individuals with well-controlled health conditions that do not affect sleep, retinal function, and\u002For well-being (e.g., well-controlled thyroid disorders, asthma, or ulcer) will not be excluded. To evaluate these criteria, potential participants will complete a locally-developed Medical History Questionnaire.\n* Past or current DSM-5 bipolar disorder or psychotic disorders. Psychiatric disorders will be evaluated using the Mini International Neuropsychiatric Interview (MINI) and the WHO-DAS 2.0, supplemented by clinical interview. We will not exclude participants for subsyndromal symptoms or disorders in these domains. We will not exclude participants for other psychiatric disorders, particularly given the high comorbidity between cannabis use disorder and major depression and anxiety disorder, as long as severity is in the moderate range or lower based on the WHO-DAS 2.0 (average score \\\u003C4).\n* Daily use of alcohol; regular use of illicit substances. Regular use (as defined above) of illicit substances other than cannabis over the past 3 months will be exclusionary. Substance use will be assessed using the Timeline Follow Back method, as well as a urine drug screen.\n* Past or current substance use disorders other than cannabis use disorder, nicotine use disorder, and mild alcohol use disorder (moderate and severe alcohol use disorder are exclusionary).\n* Current syndromal sleep disorders other than insomnia and delayed sleep phase disorder, including narcolepsy, restless legs syndrome, obstructive sleep apnea, and current night shift work (i.e., any work occurring between the hours of midnight and 6:00 a.m.). We will not exclude for subsyndromal symptoms or disorders in these domains. We will not exclude Cannabis-using participants for insomnia and delayed sleep phase disorder because of their conceptual overlap and high co-occurrence with sleep phenotypes of interest. Sleep disorders will be diagnosed according to criteria in the DSM-5 and the International Classification of Sleep Disorders, 3rd Edition, 2014. These disorders will be evaluated using clinical interview and the locally-developed Structured Clinical Interview for Sleep Disorders. Control participants will be excluded for any current sleep disorders, including insomnia and delayed sleep phase disorder.\n* Travel across 2+ time zones in the past 60 days.\n* Benzodiazepines and non-benzodiazepine hypnotic drugs (\"Z-drugs\"). Other sleep-promoting medications will be permitted, including SSRIs\u002FSNRIs, will be permitted if on stable dose and not in the acute phase of treatment. In order to evaluate medications, participants will complete a listing of current medications, including prescription and over the counter medications, \"natural\" preparations, and nutritional supplements.\n* Individuals with a Pennsylvania Medical Marijuana Card using dispensary-obtained marijuana or other THC products for documented Qualifying Medical Conditions other than those of a mental health nature will be excluded. However, individuals who have been issued a Pennsylvania Medical Marijuana ID card for a mental health condition will not be excluded from the study.\n\nThere will not be any Medical Record review. For most individuals, the Medical History Questionnaire, including medical conditions and medications, will be sufficient for identifying exclusionary medical criteria. For instances where an individual is uncertain about exclusionary or current medical conditions or medications, medical records, prescription records or labeled prescription pill bottles, or a Release of Information to contact the individual's Primary Care Practitioner \\[PCP\\] to clarify the individual's medical status will be obtained.","25 Years",{"count":471,"type":23},180,[116],"The goal of this study is to learn how cannabis use and discontinuation affect sleep, circadian rhythms, and sensitivity to light. The main questions it aims to answer are:\n\n1. Does cannabis use and discontinuation impact sleep drive?\n2. Does cannabis use and discontinuation impact light sensitivity and circadian phase?",[27,475,476],"Sleep","Circadian Rhythm",[94,478,479,480,481],"sleep","circadian rhythms","photosensitivity","cannabis discontinuation","2026-04-03",{"date":484,"type":38},"2026-04-06",{"date":486,"type":38},"2025-03-13",{"date":488,"type":23},"2029-04-30",{"name":490,"class":45},"University of Pittsburgh",{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":158,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":56,"phases":500,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":46},"100583963","phase-3-cannabis-tobacco-co-use-treatment-study-100583963","NCT06883162","Cannabis-Tobacco Co-Use Treatment Study","Randomized Controlled Trial of Varenicline to Treat Tobacco and Cannabis Co-Use (RECLAIM)","RECLAIM","Inclusion criteria:\n\n1. Ages 18 and over (no upper age limit)\n2. Must smoke at least 5 tobacco cigarettes per day on at least 20 out of the past 30 days for the past 3 months\n3. Must express interest in quitting tobacco\n4. Must express interest in cannabis reduction and\u002For cessation\n5. Must submit a positive instant-read test for cotinine and cannabis prior to enrollment\n6. Must self-report cannabis use (THC-dominant products) on at 3 days per week out of the past 30 days\n7. Must be willing to take varenicline or placebo for 12 weeks\n8. Must reside in South Carolina\n\nExclusion criteria:\n\n1. Any significant or acutely unstable medical, psychiatric, or substance use problem (including clinically significant disorders) that would contraindicate research, interfere with safety, compromise data integrity, or preclude consistent study participation\n2. Pregnant or trying to become pregnant\n3. Use of medications with smoking cessation efficacy\n4. Regular use of e-cigarettes or other tobacco products (\\\u003C10 days in the past month)",{"count":22,"type":23},[501],"PHASE3","The purpose of the RECLAIM study is to evaluate the effectiveness of varenicline (sometimes known as Chantix) compared to placebo (an inactive substance) for the treatment of cigarettes and cannabis (marijuana). Varenicline is not FDA approved for the combination treatment of cigarette abstinence and cannabis reduction or abstinence. All participants will also receive counseling and access to online treatment modules during a quit attempt for cigarettes and a reduction attempt for cannabis. This study is being conducted by the Medical University of South Carolina. All procedures are conducted remotely and there is no in-person visits are needed.\n\nTo qualify, participants must be 18 or older, live in South Carolina, use cigarettes and cannabis, and are interested in quitting cigarettes and reducing cannabis.",[504,505,27,29,128],"Tobacco Use Disorder","Tobacco Use Cessation","2026-04-02",{"date":482,"type":38},{"date":509,"type":38},"2025-05-06",{"date":511,"type":23},"2029-01-01",{"name":513,"class":45},"Medical University of South Carolina",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":469,"enrollmentInfo":521,"targetDuration":4,"studyType":56,"phases":523,"briefSummary":525,"conditions":526,"keywords":527,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":418},"100593087","phase-4-cannabis-potency-effects-on-brain-white-matter-in-early-phase-psychosis-100593087","NCT07001878","Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis","Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis: A Pilot Feasibility Treatment Study","Inclusion Criteria:\n\n* This study will enroll individuals 18-25 years of age from the Nova Scotia Early Psychosis Program\n\nExclusion Criteria:\n\n* Current stimulant use disorder",{"count":522,"type":23},24,[524],"PHASE4","Canada reports some of the highest rates of cannabis use in our youth and young adult populations, among all the developed countries. Recent Health Canada surveys report that 27% of 16-19-year-olds and 32% of 20-24-year-olds have used cannabis in the past 30 days, with 16-24-year-olds showing the highest rates of daily or near-daily use. Unfortunately, cannabis use has also been found to be a risk factor for the development of a psychotic disorder in emerging adults, and in those who develop psychosis and continue cannabis use, there is a significant effect on long term outcomes. This includes the severity of symptoms, risks of relapse (being hospitalized) and not reaching a level of functioning that would be expected. Lifetime experience with cannabis is greater than 80% in young adults with early phase psychosis (EPP; the first 5 years of a psychosis illness) with up to 30% of Canadian EPP patients meeting criteria for a diagnosis of cannabis use disorder (CUD) at entry to care. A recent Canadian population-based study found that cannabis use disorder associated to psychosis has risen from 3.7% pre-2018 to 10.3% at present. There has been a significant increase in Δ9-tetrahydrocannabinol (THC) levels in cannabis products available globally over the years, with popular cannabis products available start as high as 18% THC in Canada. However high potency cannabis carries a more significant risk for psychosis development, as well as higher risk for cannabis dependence and other severe mental health issues.\n\nA major gap in the research is a specific focus on cannabis potency on brain white matter (WM) in youth and young adults, and if there are any potential treatment strategies that could be used to influence any of these cannabis WM effects. To address this, a medication called metformin, that is already used in psychosis to help with side effects of antipsychotic medications, will be used as it has also shown promise to influence WM changes in other illnesses. This project is thus focused on naturalistic cannabis potency effects on WM in emerging adults in EPP (divided into three groups; those using high potency cannabis, low potency cannabis, and minimal cannabis use) and treating them with metformin for 6 months and assessing effects on neuroimaging, cognitive and clinical variables.\n\nThe purpose of this pilot feasibility study is to inform the development\u002Frefinement of an intervention protocol, and not to test potential effects or mechanisms as the sample size will have insufficient power to perform an in-depth analysis. The results of this work will inform our research strategy development and assess feasibility of our novel methodological approach.\n\nParticipants will:\n\n1. Visit the clinic at baseline, 3 months (only Timeline Follow-Back Assessment administered), and 6 months post baseline to complete substance use and mental health questionnaires, and cognitive assessments\n2. Complete an MRI scan at baseline and 6 months\n3. Take Metformin every day for 6 months",[257,27],[94,528,529,530],"metformin","early phase psychosis","potency","2026-04-01",{"date":533,"type":38},"2026-04-07",{"date":535,"type":38},"2025-03-18",{"date":537,"type":23},"2026-12-01",{"name":539,"class":45},"Nova Scotia Health Authority",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":548,"minAge":19,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":56,"phases":550,"briefSummary":551,"conditions":552,"keywords":555,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":46},"100630574","feasibility-and-acceptability-trial-to-reduce-tobacco-and-cannabis-use-during-pregnancy-and-postpartum-100630574","NCT07489443","Feasibility and Acceptability Trial to Reduce Tobacco and Cannabis Use During Pregnancy and Postpartum","Partnering With Pregnant and Postpartum People to Co-Create a Novel Intervention to Reduce Tobacco and Cannabis Use","PICTURe","Inclusion Criteria:\n\n* Confirmed pregnant\n* Under 26 weeks gestation\n* Plan to remain pregnant\n* English speaking\n* Use of combustible tobacco at least once a week during pregnancy, or at least once a week in the 3 months before pregnancy if stopped\n* Use of cannabis at any frequency during pregnancy or in the 3 months before pregnancy if stopped\n\nExclusion Criteria:\n\n* Current opioid use or active treatment for Opioid Use Disorder\n* Unable to provide informed consent in English\n* Under 18 years old","FEMALE",{"count":7,"type":23},[116],"Using both tobacco and cannabis during pregnancy is more common in minoritized groups and can make quitting smoking in pregnancy and remaining smoke free postpartum difficult. Investigators will test an intervention to address prenatal depressive symptoms to encourage people to quit tobacco and cannabis during pregnancy and stay quit postpartum.",[553,27,448,554],"Perinatal","Smoking Cessation",[556,557,558,559,560,561,94,562],"tobacco","perinatal","pregnancy","smoking","cessation","postpartum","intervention","2026-03-17",{"date":565,"type":38},"2026-03-24",{"date":567,"type":23},"2026-04",{"date":569,"type":23},"2027-10",{"name":490,"class":45},{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":18,"minAge":579,"maxAge":112,"enrollmentInfo":580,"targetDuration":4,"studyType":56,"phases":581,"briefSummary":582,"conditions":583,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":591,"locationsCount":46},"100476614","cars-cannabis-and-alcohol-reduction-study-100476614","NCT05486234","CARS: Cannabis and Alcohol Reduction Study","Brief Computerized Intervention for Reducing Adolescent Cannabis and Alcohol Use","CARS","Inclusion Criteria:\n\n* between the ages of 13 and 17\n* be seeking treatment for either cannabis or alcohol use;\n* report co-occurring alcohol and cannabis use during the past three months (i.e., participants who report using both alcohol and cannabis during the three months prior to participation in the study, regardless of if the use was simultaneous)\n* have a caregiver willing to participate and provide consent.","13 Years",{"count":5,"type":23},[116],"The study will test a computerized treatment with subjects ages 13-17 years who are seeking treatment for alcohol and\u002For cannabis use. Follow-up assessments will be conducted at one- and three-months following treatment.",[27,584,136,137],"Alcohol Use, Unspecified","2026-03-05",{"date":587,"type":38},"2026-03-09",{"date":589,"type":38},"2023-01-25",{"date":289,"type":23},{"name":513,"class":45},{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":158,"sex":599,"minAge":19,"maxAge":251,"enrollmentInfo":600,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":601,"conditions":602,"keywords":604,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":46},"100628256","psychiatric-symptom-characteristics-in-methamphetamine-induced-psychosis-with-and-without-lifetime-cannabis-use-100628256","NCT07459270","Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use","Investigation of Factors Associated With Psychiatric Symptoms in Participants Diagnosed With Methamphetamine-Induced Psychotic Disorder With and Without Lifetime Cannabis Use","1. For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group:\n\n   \\*Inclusion Criteria:\n\n   • Diagnosis of MP according to DSM-5-TR\n   * Diagnosis of Cannabis Use Disorder according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n\n   • Diabetes mellitus\n\n   • Chronic kidney disease\n\n   • Rheumatoid arthritis\n\n   • Systemic lupus erythematosus\n\n   • Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder\n2. For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group:\n\n   \\*Inclusion Criteria:\n\n   • Diagnosis of MP according to DSM-5-TR\n\n   • Medication-free for at least one month prior to admission\n\n   • Age ≥ 18 years and \\\u003C65 years\n\n   • Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n\n   • Diabetes mellitus\n\n   • Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder","MALE",{"count":227,"type":23},"This prospective cohort study aims to investigate factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP) with and without lifetime cannabis use (LCU). Participants hospitalized at Elazığ Mental Health and Diseases Hospital who meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for MP will be included.\n\nParticipants will be divided into two groups based on the presence or absence of LCU. Psychiatric symptoms and clinical characteristics will be assessed weekly during an eight-week inpatient follow-up period using standardized psychometric instruments.\n\nThe study aims to determine whether LCU influences the course and severity of psychiatric symptoms in MP and to identify environmental, individual, and familial factors associated with symptom progression.",[603,27],"Methamphetamine Induced Psychosis",[605,63,126,606,607,608,609],"Methamphetamine","Psychiatric Symptoms","Longitudinal Study","Methamphetamine-Induced Psychotic Disorder","Lifetime Cannabis Use","2026-03-04",{"date":587,"type":38},{"date":613,"type":23},"2026-03-16",{"date":615,"type":23},"2026-11-23",{"name":617,"class":618},"Elazığ Mental Health and Diseases Hospital","OTHER_GOV",{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":158,"sex":18,"minAge":626,"maxAge":627,"enrollmentInfo":628,"targetDuration":4,"studyType":56,"phases":630,"briefSummary":631,"conditions":632,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":418},"100569823","effectiveness-of-brief-intervention-in-primary-care-for-diverse-young-people-chat-100569823","NCT06699251","Effectiveness of Brief Intervention in Primary Care for Diverse Young People (Chat)","Effectiveness of Brief Intervention in Primary Care for Diverse Young People","Inclusion Criteria:\n\n* receive health care at one of two participating health systems\n* aged 12-17\n* screen positive for being at risk for alcohol or cannabis use using the CRAFFT\n\nExclusion Criteria:\n\n* if they don't meet the inclusion criteria, they will be excluded","12 Years","19 Years",{"count":629,"type":23},500,[116],"Brief motivational interviewing intervention to address alcohol use among diverse teens 12-17.",[633,27],"Adolescent Drinking",{"date":635,"type":38},"2026-03-06",{"date":637,"type":38},"2025-04-28",{"date":639,"type":23},"2029-02-28",{"name":641,"class":45},"RAND",{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":648,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":18,"minAge":626,"maxAge":19,"enrollmentInfo":650,"targetDuration":4,"studyType":56,"phases":651,"briefSummary":652,"conditions":653,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":662,"locationsCount":46},"100560356","cannabis-linked-emotions-and-adolescent-risk-study-100560356","NCT06576076","Cannabis, Linked Emotions, and Adolescent Risk Study","Characterizing Proximal Risk for Depressive Symptoms and Suicidal Ideation With Acute Cannabis Use and Withdrawal Among Adolescents Using Ecological Momentary Assessment","CLEAR","Inclusion Criteria:\n\n* Ages 12-18;\n* Current daily or near daily cannabis use (i.e., use ≥ 4 days per week on average; Timeline Followback);\n* Score ≥ 5 on PHQ-9;\n* Access to an internet-capable smartphone (iOS or Android);\n* Provision of at least 1 collateral contact for risk monitoring;\n* Provision of informed assent (or consent if 18 years or older) and parent\u002Fguardian consent if \\\u003Cage 18;\n* Greater than 50% response rate to EMA prompts during the first EMA phase;\n* No immediate plan to discontinue cannabis use in the next 3 months;\n* Positive toxicology result for cannabis on baseline urinalysis.\n\nExclusion Criteria:\n\n* Any factor that impairs ability to comprehend and effectively participate, including acute intoxication at time of consent;\n* Cannabis use \\>4 times\u002Fday on average (to maximize likelihood of capturing mood and SI during non-use times);\n* Inability to speak\u002Fwrite English fluently;\n* Gross cognitive impairment, for example due to florid psychosis, intellectual disability, developmental delay, or neurodegenerative disease;\n* Current epilepsy diagnosis;\n* Individuals who are under the legal protection of the government or state (wards of the state);\n* Response of \"No\" to the knowledge check question regarding EMA suicidality response time;\n* Inability to wear Fitbit device.",{"count":22,"type":23},[116],"The goal of this study is to disentangle relationships between acute cannabis use and withdrawal on proximal depression and suicide risk and recovery in adolescents ages 12-18 years by incorporating time-varying patterns of substance use, mood, and SI. This project aims to guide the development of scalable, individualized, accessible, and affordable interventions aimed to reduce depression and suicide risk among adolescents.",[27,306,654,655],"Suicidal Ideation","Adolescent Behavior","2026-02-27",{"date":658,"type":38},"2026-03-03",{"date":660,"type":38},"2025-02-18",{"date":488,"type":23},{"name":663,"class":45},"Massachusetts General Hospital"]